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Abstract P79 [1] was published in error and the correct
text follows:
Background
Right heart failure is a prevalent mechanism of cardio-
vascular collapse and distinctly different from left heart
failure. Afterload reduction has been the main focus to
treat right ventricular (RV) dysfunction, but it cannot be
achieved in many cases. A new strategy is to directly
target increased RV hypertrophy. Pulmonary artery
banding (PAB) is used to induce the RV hypertrophy,
without any changes in the pulmonary vasculature. The
nitric oxide (NO) pathway was shown to be crucially
involved in the development of left ventricular hypertro-
phy. In this study we assessed the effects of the sGC sti-
mulator BAY 41-8543, the PDE5 inhibitor sildenafil, and
combination treatment on RV function and RV
hypertrophy.
Methods
Chronic pressure-overload RV hypertrophy was induced
by PAB in male C57/Bl6 wild-type mice. Drug treatment
was started seven days after surgery for the duration of
2 weeks, after which the consequences of the sustained
pressure overload on RV morphology and function were
assessed using Magnetic Resonance Imaging (MRI) and
RV catheterization. Furthermore, fibrosis was assessed
by histology.
Results
Three weeks after PAB, placebo-treated mice showed
several signs of RV dysfunction as compared to sham-
operated mice. PAB led to RV systolic dysfunction, as
indicated by an increase in end-systolic volume (17.3
±1.0 ml vs. 29.2±2.5 ml [Sham vs. PAB]), decreased RV
stroke volume (40.5±2.3 ml vs. 23.0±3.3 ml) and
decreased RV ejection fraction (70.0±1.0 % vs. 43.0±3.5
%). Treatment with sildenafil did neither lead to signifi-
cant changes in RV end-systolic volume, RV stroke
volume nor RV ejection fraction, whilst treatment with
BAY 41-8543 and combination treatment led to signifi-
cant improvements. (RV end-systolic volume: 29.2±2.5
vs. 23.6±3.3 vs. 24.6±1.1 vs. 19.1±3.8; RV stroke volume:
23.0±3.3 vs. 27.3±2.3 vs. 32.1±3.8 vs. 31.8±1.3; RV ejec-
tion fraction: 43.3±3.5 vs. 54.1±3.0 vs. 55.7±3.7 vs. 63.8
±4.4 [all values as %; placebo vs. sildenafil vs. BAY 41-
8543 vs. combination treatment]). PAB mice showed RV
hypertrophy (0.022±0.003g vs. 0.032±0.006g) and an
increased RV/(LV-S) ratio (0.25±0.03 vs. 0.39±0.1). Drug
treatment had no effects on either RV hypertrophy nor
RV/(LV+S) ratio. RV pressure was increased in PAB
mice (30.0±3.0 mmHg vs. 50.8±12.2 mmHg) and did
not change under drug treatment. Histological assess-
ment of fibrosis showed that the collagen content
increased in banded mice, sildenafil had no effects on
collagen content, and BAY 41-8543 and combination
treatment both decreased the amount of collagen (7.6
±2.1 vs. 1.2±0.1 8.8±5.8 vs. 3.3±1.2 vs. 3.3±1.2 [all values
as %; placebo vs. sham vs. sildenafil vs. BAY 41-8543 vs.
combination treatment]).
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Even though none of the drug treatments led to signifi-
cant changes in RV mass, BAY 41-8543 and combina-
tion treatment with sildenafil led to significant
improvements in RV function, accompanied by
decreased fibrosis.
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